PUVA Therapy for Vitiligo: How It Compares to Narrowband UVB
PUVA therapy — psoralen plus ultraviolet A — was the dominant phototherapy approach for vitiligo from the 1970s through to the 2000s. Narrowband UVB has largely replaced it in most clinical guidelines, but PUVA remains in use in some settings and has specific situations where it is preferred. Understanding what it is, how it compares to NbUVB, and when it might still be appropriate helps patients who encounter it as a recommendation.
What is PUVA?
PUVA combines two components:
Psoralen: A photosensitising compound derived from plant sources (originally from the psoralen plant family, including bergamot and celery). Psoralens sensitise the skin to UVA radiation, making it dramatically more responsive to UV than it would be without the drug. Psoralens can be taken orally (oral PUVA) or applied directly to the skin (topical PUVA, also called bath PUVA or topical application before exposure).
UVA radiation: Long-wavelength ultraviolet light (320–400nm). UVA penetrates more deeply into the skin than UVB but causes less surface burning without psoralen. With psoralen, it produces a powerful photochemical reaction that suppresses T cell activity and stimulates melanocyte proliferation — the same goals as narrowband UVB but through a different mechanism.
How PUVA works in vitiligo
The mechanism is similar to NbUVB in outcome but different in pathway. Psoralen molecules intercalate into DNA when activated by UVA light, producing photoadducts that inhibit DNA replication in activated T cells. This selectively suppresses the autoimmune attack on melanocytes. Simultaneously, melanocyte stimulation occurs through the UV-melanocyte pathway, encouraging perifollicular repigmentation.
PUVA vs narrowband UVB: the comparison
Efficacy
Both produce comparable repigmentation rates in the best-responding areas (face, neck). Narrowband UVB may have a slight edge in response rates in some body areas; head-to-head comparative studies give varying results.
The more important difference is not efficacy but safety.
Safety profile
NbUVB has a substantially better long-term safety profile than PUVA:
Carcinogenicity: Oral PUVA is classified as a probable human carcinogen by the IARC. Long-term use (more than 150–200 PUVA sessions over a lifetime) significantly increases the risk of squamous cell carcinoma. NbUVB does not carry the same carcinogenicity risk — it is considered a much safer long-term phototherapy option.
Eye protection: Psoralens sensitise the lens of the eye to UV, raising the risk of cataracts. Patients on oral PUVA must wear UV-blocking sunglasses for the entire day of each treatment to prevent cataract formation. NbUVB does not require the same precaution (though eye protection during phototherapy sessions is still required).
Nausea and gastrointestinal effects: Oral psoralen causes nausea in a proportion of patients. Topical PUVA (applying psoralen only to the skin rather than taking it orally) reduces this problem.
Skin aging: PUVA treatment accelerates photoaging of the skin more than NbUVB, due to the deeper penetration of UVA and the psoralen amplification of UV effects.
Availability
NbUVB lamps are widely available for home use, making consistent treatment accessible without clinic visits. PUVA requires timing the UV exposure to the psoralen pharmacokinetics (peak photosensitisation occurs one to two hours after oral ingestion), making home PUVA much less practical. PUVA is primarily a clinic-based treatment.
When PUVA is still used
Given NbUVB’s better safety profile and comparable efficacy, why would anyone still use PUVA? There are a few remaining clinical niches:
Extensive skin-type VI disease: In patients with very dark skin (Fitzpatrick type VI), the higher UVA doses that PUVA can safely deliver may produce better penetration and melanocyte stimulation in some cases. This is not a universal preference — many centres use NbUVB for all skin types — but some clinicians report advantages in specific patients.
Bath PUVA: Topical psoralen applied as a bath or lotion immediately before UVA exposure avoids systemic psoralen exposure. Risks are reduced (no oral nausea, reduced systemic carcinogenicity). Some UK and European centres use bath PUVA as an intermediate option between the systemic risks of oral PUVA and the lower response rates of NbUVB in specific anatomical areas.
Oral PUVA when NbUVB has failed: For patients who have not responded to a full course of narrowband UVB, PUVA may be tried as a second-line option. The different mechanism may produce response in some NbUVB non-responders.
Topical PUVA for small patches
Topical PUVA — applying a dilute psoralen solution to a small patch area and then exposing only that area to UVA — is lower-risk than oral PUVA and can be done in a clinic without systemic psoralen. For patients with limited focal vitiligo who do not have access to excimer laser, this can be an option. However, it requires precise timing of the UVA exposure after topical application to catch peak photosensitisation.
Current clinical role
PUVA is no longer first-line for vitiligo in most international guidelines, which now recommend narrowband UVB as the preferred phototherapy. The switch happened primarily for safety reasons, not efficacy reasons.
Patients who are offered PUVA should ask their dermatologist specifically whether NbUVB has been considered and why PUVA is being recommended over it. In most cases, NbUVB is the appropriate first choice. PUVA remains in the toolkit for second-line use and specific clinical situations.
Home narrowband UVB phototherapy is covered in detail for patients who are considering home phototherapy as an option. The narrowband UVB vs excimer laser comparison covers the choice between different phototherapy approaches. The vitiligo treatment options comparison gives the broader treatment landscape.
